Form 8-K CRISPR Therapeutics AG For: Oct 28
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Chardan Capital Markets Reiterates Buy Rating on CRISPR Therapeutics (CRSP)
October 28, 2019 10:25 AM EDTChardan Capital Markets analyst Geulah Livshits reiterated a Buy rating and $72.50 price target on CRISPR Therapeutics (NASDAQ: CRSP) after the comapny announced 3Q19 results and provided updates on clinical programs, with dosing initiated in the phase I/II trial (NCT04035434) of allogeneic CAR-T CTX110 in CD19+ cancers, and the follow-on asset, CTX120, targeting BCMA set to... More
